Multiparticulate Dual-Release Combination Tablets: A Promising Approach for Chronomodulated and Patient -Centric Drug Delivery

Multiparticulate dual-release combination tablets represent an advanced drug delivery platform designed to optimize therapeutic outcomes and enhance patient compliance by synchronizing drug release with the body’s circadian rhythms. These systems incorporate both immediate-release (IR) and controlled/modified-release (CR/MR) components within a single dosage form, ensuring a rapid onset of action followed by sustained drug release over an extended period. This dual functionality is particularly beneficial in managing chronic and time-dependent diseases such as hypertension, asthma, and arthritis, where symptom severity varies throughout the day. Typically, these formulations employ multiparticulate technologies such as pellets, granules, or mini-tablets, which are either filled into capsules or compressed into tablets. Such approaches provide several advantages, including uniform drug distribution, reduced risk of dose dumping, improved gastrointestinal transit, and flexible modulation of release profiles. Various formulation strategies—such as polymer coating, extrusion-spheronization, and compression coating—are used to achieve the desired release kinetics. Evaluation of these systems involves parameters like flow properties, hardness, friability, drug content, dissolution studies, and stability testing to ensure consistent performance and product quality. Importantly, multiparticulate dual-release systems offer patient-centric benefits, including reduced dosing frequency, minimized side effects, and improved adherence to therapy. With ongoing advancements in novel polymers and drug delivery technologies, these systems hold significant promise for chronotherapeutic applications and personalized medicine, paving the way for more effective and targeted treatment strategies .